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A B S T R A C T
Covalent linking of immunogenic oligopeptides with synthetic Toll-like receptor ligands is a useful approach to
develop self-adjuvanting vaccines. In particular, small-molecule based agonists of Toll-like receptor 7 (TLR7)
that are derived from 8-oxo-adenine core are potentially promising because these chemically robust TLR7 li-
gands can be connected to peptide T-cell epitopes via straightforward solid-phase peptide synthesis. In this
contribution we present the synthesis of a Boc-protected 9-benzyl-2-alkoxy-8-oxo-adenine building block and its
application in the online solid phase synthesis of three peptide conjugates that differ in the position of the TLR7
ligand within the peptide. The conjugates are able to induce dendritic cell maturation and T cell proliferation
while the position of the ligand impacts T cell proliferation potency.
Toll-like receptors (TLRs) are part of the mammalian innate immune
system that forms the first line of defence against pathogens by re-
cognising pathogen associated molecular patterns (PAMPs).1 Upon re-
cognition of a specific PAMP by the corresponding TLR, a signal
transduction pathway is started that activates the immune system. Ten
different human TLRs can be discerned that are situated either at the
cell surface (TLR1, TLR2, TLR4, TLR5 and TLR6) or in intracellular
compartments (TLR3, TLR7, TLR8 and TLR9).2 Each TLR recognizes
PAMPs of certain structural identity and intracellular TLRs bind to
nucleic acids of various origin. TLR8 binds to viral and bacterial
RNA.3,4 TLR9 recognizes bacterial and viral single stranded DNA, the
latter is also recognized by TLR7.5,6 As modulators of the immune
system TLR ligands are important drug targets and much research has
been directed to the development of small-molecule TLR agonists.7 A
prime example of a TLR7 agonist is imiquimod8 that is used for topical
treatment of a variety of skin diseases.9,10 In the last decade struc-
ture–activity studies on small molecules have resulted in specific and
non-specific agonists for TLR7 and TLR8. Well known examples are
represented by imidazoquinolines (e.g. imiquimod) and 8-oxo-adenine
derivatives.11,12 These agonists, either as such or conjugated to other
molecular entities have been explored as adjuvants in the framework of
the development of new vaccines and immunotherapies.11,13,14 For
example, to improve the potency and/or to prevent toxic side effects
TLR7 ligands are conjugated to macromolecules such as phospholipids,
polysaccharides and peptides.15,16 One approach towards the develop-
ment of fully synthetic vaccine modalities is directed to the design,
synthesis and evaluation of conjugates, comprising a structurally de-
fined TLR agonist, covalently connected to an oligopeptide epitope.
Several of these conjugates exhibit improved immunological prop-
erties in comparison with a mixture of the composing components.18–20
Such conjugates in which a TLR7 ligand is covalently connected to an
antigenic peptide have been prepared as well. We synthesized azide-
containing analogues 1b-g of the TLR7 ligand 9-benzyl-8-oxo-2-bu-
toxyadenine 1a, that can be applied in the synthesis of conjugates
(Fig. 1).17,21 For instance, copper(I) catalysed cycloaddition of 1b to the
appropriate alkynyl-peptide gave conjugate 2 featuring – besides the
TLR7 ligand – the murine cytotoxic T lymphocyte epitope, SIINFEKL.17
Although this conjugate give rise to enhanced antigen presentation in
vitro, it unexpectedly lack the ability to induce maturation of dendritic
cells (DC). The latter action is crucial for the induction of T-cell
mediated immunity. The position in the TLR7 agonist to which the
peptide epitope is connected proved to be of prime importance for the
immunological activity of the resulting conjugate: Jin and co-workers
revealed that attachment of the 8-hydroxyadenine based TLR7 agonist
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via its 9-benzyl moiety to an oligopeptide did mediate DC activation.15
Here we describe the synthesis of three conjugates (Fig. 1, 3–5), in
which the well-established TLR7 ligand 9-benzyl-8-oxo-2-butoxy-ade-
nine11,22 is covalently connected through its 9-benzyl moiety to the CTL
(SIINFEKL) epitope. A derivative of 9-benzyl-8-oxo-2-butoxy-adenine
having a carboxyl function at the para position of the benzyl moiety was
used for the covalent attachment of the TLR7 ligand to the N-terminus
of OVA-derived peptide DEVSGLEQLESIINFEKL to give conjugate 3.
The same TLR7 ligand was installed at both the N-terminus and at the
side chain of the C-terminal lysine residue in DEVSGLEQLESIINFE-
KLA5K to give conjugates 4 and 5, respectively. The A5K extension on C-
terminus of the peptide is introduced to allow a comparison of the
immunological activity of the conjugates having the TLR7 agonist in-
stalled at either the N-terminus or close to the C-terminus of the epitope
containing peptide. Such design of the conjugates was used by us in the
previous studies and it was demonstrated that the presentation of the
CTL-epitope was not precluded.17 An ethylene glycol spacer, exhibiting
minimal steric hindrance is selected for its favourable influence on the
biological activity of the TLR7 ligand upon conjugation, as was shown
in previous studies.16
The assembly of the projected conjugates (3–5) was performed with
the aid of an automated synthesizer using a solid phase peptide
synthesis (SPPS) protocol. To achieve this, the previously reported
carboxyl functionalized TLR7 ligand 11 (Scheme 1) was prepared by
adaption of published procedures.11,17,21,23 However, in our hands this
building block proved to be unsuitable for SPPS due to its poor solu-
bility as previous described.16 A major improvement was achieved by
protection of the purine base by a Boc group to give soluble building
block 12 that could be used successfully in a SPPS setting (Scheme 1). In
the first step of the synthetic route to 12 commercially available 2-
chloroadenine 7 was selectively benzylated at the N-9 position using
alkylating reagent 6 (Scheme 1). This reagent was prepared by acid
Fig. 1. TLR7 ligand (1) and its conjugate (2) synthesized previously17 by us and TLR7 conjugates 3, 4 and 5 that are subject of the here-presented studies.
Scheme 1. Synthesis of compound 12. Reagent and conditions: i) 1M TBAF in
THF, RT, 92% ii) 1) NaH, n-BuOH, 120 °C 2) H2SO4, 80 °C, 71% iii) Br2, NaOAc,
DCM, 94% iv) NaOH, H2O, MeOH, reflux, 89% v) NaOH, Boc2O, H2O, dioxane,
35%.
Scheme 2. Synthesis of conjugate 3. Reagents and conditions: i) standard SPPS
synthesis ii) 12, HCTU, Dipea, NMP iii) TFA/H2O/TIS (95/2.5/2.5).
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mediated condensation of p-toluic acid and n-butanol, followed by ra-
dical bromination of the obtained ester, using N-bromosuccinimide and
AIBN (See Supporting Information). It was established that benzylation
of 2-chloroadenine 7 with bromide 6 using 1M TBAF in THF out-
performed procedures featuring bases other than TBAF. For instance,
both selectivity and yield dropped when K2CO3 was used as a base. The
quality of the TBAF/THF solution, most likely its water content, influ-
enced the yield of benzylation of the N-9 position of the adenine deri-
vative.17,21 Nucleophilic aromatic substitution of 2-chloroadenine de-
rivative 8 with sodium n-butoxide at 120 °C was accompanied by partial
hydrolysis of the butyl ester. The butyl ester was recovered by acid-
ifying the crude reaction mixture with H2SO4 and heating it at 80 °C for
2 h to give adenine derivative 9. Electrophilic aromatic substitution of
9, using elementary bromine under mild basic conditions gave 10 in
high yield. Subsequent direct hydrolysis of the bromine at the C-8 po-
sition in 10 with aqueous NaOH was unsuccessful, however, when 10
was refluxed for three days in a mixture of water and methanol the
product 11 could be obtained. Compound 11, which appeared to be
insoluble in most solvents, was isolated by precipitation from aqueous
acidic solution followed by collection of the sticky precipitate by cen-
trifugation, washing the precipitate with dilute hydrochloric acid and
drying. The impracticability of 11 forced us to consider protection of
the purine base in 11 with a SPPS compatible protecting group. Due to
the poor solubility of 11 introduction of Boc or trityl protections proved
to be cumbersome. Firstly, we tried 2-(Boc-oxyimino)-2-phenylaceto-
nitril (Boc-ON) as the reagent to introduce a Boc protection to the ox-
oadenine core but this reaction proceeded sluggishly and required long
reaction times. After five days of stirring at room temperature with a
ten-fold excess of the reagent, LC-MS analysis indicated approximately
50% conversion and after purification 12 was obtained in only 10%
yield. This low isolated yield is probably due to an insufficient solubility
of 12 in dichloromethane that has been used to recover the product
Scheme 3. Synthesis of conjugates 4 and 5. Reagents and conditions: i) standard SPPS synthesis; ii) 12, HCTU, DIPEA, NMP; iii) TFA/H2O/TIS (95/2.5/2.5); iv) 1%
TFA, DCM.
Fig. 2. Induction of dendritic cell maturation by TLR7 conjugates was measured by IL-12p40 cytokine production (A) and expression of the costimulatory molecule
CD86 (B), at 5 µM. Resiquimod is a marketed TLR7/8 agonist and was used here as comparison to the oxoadenine TLR7 ligand used in conjugates 3–5. For IL-12p40,
means of two independent experiments ± SEM are reported. Statistical significance was determined for the conjugates versus peptide at the same concentration by
one-way ANOVA, followed by multiple comparison with Bonferroni correction. *p < 0.05, **p < 0.01, ***p < 0.001.
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after work up with aqueous acid (10% KHSO4). A major improvement
was achieved by dissolving 11 in an aqueous NaOH solution followed
by dropwise addition of di-tert-butyl dicarbonate (Boc2O), subsequent
neutralisation of the reaction with HCl allowed the removal of the ex-
cess reagent and finally Soxhlet extraction gave 12 (30–40%) and re-
generated starting material 11 (∼50%). Although the yield of this final
protection was somewhat low, the fact that starting material 11 could
be regenerated made this approach practical and allowed preparation
of 12 in gram quantities. The improved solubility of 12 over 11 in or-
ganic solvents made 12 the preferred building block for the forth-
coming SPPS.
Having the functionalized TLR7 ligand 12 available, SPPS of con-
jugate 3 was performed starting from Tentagel® S PHB resin, and using
Fmoc chemistry with HCTU as the condensing agent and commercially
available protected amino acid building blocks (Scheme 2). After
completion of the DEVSGLEQLESIINFEKL sequence, the Fmoc group at
the N-terminus of the immobilized oligopeptide was removed and
Fmoc-protected aminodiethyleneglycol linker was introduced and de-
protected using the same conditions as used for the standard Fmoc
amino acids. In the final step Boc-protected TLR7 ligand 12 was cou-
pled to the unmasked amine using HCTU as the condensing agent. Fi-
nally, removal of all protecting groups and cleavage from the resin was
achieved with a TFA to give after RP HPLC purification target conjugate
3 in a yield of 10%. Conjugates 4 and 5 (see Figure 1) were prepared
and purified using the same SPPS conditions as described for conjugate
3 but starting with Tentagel® S RAM amide resin, to which Fmoc-Lys
(Mmt)-OH was coupled as the first amino acid (Scheme 3). For con-
jugate 5 the N-terminus was acetylated after completion of the DEVS-
GLEQLESIINFEKLA5K sequence, Mmt cleavage and elongation of the
lysine side chain by introduction of the glycol linker followed by
introduction of Boc protected TLR7 ligand 12. Removal of all protection
groups and cleavage from the resin followed by purification gave con-
jugates 4 and 5 in 12% and 10% yield respectively. Next, the conjugates
were evaluated for their ability to induce dendritic cell maturation and
T-cell proliferation. Conjugation at the para-position of the benzyl
moiety of the TLR7 ligand preserved its ability to promote dendritic cell
maturation, as demonstrated by both production of IL-12p40 (Fig. 2A)
and a strong upregulation of membrane expression of the costimulatory
molecule CD86 (Fig. 2B). All conjugates were functional although their
activity was slightly lower compared to the free ligand. Both N-terminal
conjugates 3 and 4 showed activity down to a concentration of 600 nM.
In comparison, the C-terminal conjugate (5) displays higher activity
down to 160 nM concentration. A crucial step for induction of T cell
immunity is represented by uptake and correct processing of the pep-
tide moiety by dendritic cells. This step should lead to epitope pre-
sentation (here: the SIINFEKL epitope) by surface MHC molecules to
specific T cells. The ability of the conjugates to induce T cell pro-
liferation was tested in vitro with SIINFEKL-specific OT1 T cells. Den-
dritic cells were pulsed with the conjugates or the unconjugated com-
ponents and exposed to CFSE-labelled OT1. After three days, OT1
proliferation was measured as CFSE dilution in individually divided
cells (Fig. 3 A). The three conjugates all induced significantly enhanced
T cell proliferation when compared to unconjugated peptide or a mix of
TLR7 ligand and peptide(Fig. 3B). In comparison, the conjugates with
the ligand at the N-terminal position (conjugates 3 and 4) performed
better than the C-terminal conjugate (conjugate 5) as shown by the
mean division index (Fig. 3B).
To conclude, we here describe that the TLR 7 ligand 9-benzyl-8-
hydroxy-2-butoxy-adenine functionalized with a carboxyl group at the
para position of the benzyl moiety (i.e. 11) was made suitable for SPPS
Fig. 3. Antigen processing and presentation of the conjugates by dendritic cells was measured by proliferation of SIINFEKL-specific OT1 T cells. OT1 cells were
intracellularly labelled with the CFSE fluorophore and cellular division was measured as cumulative dilutions of CFSE signal. A) Representative proliferation profile
of one experiment out of three performed, displayed for 10 nM concentration of each compound. B) Mean division index of OT1 cells upon co-culture with dendritic
cells incubated with 5, 10 and 50 nM of the indicated compounds. Significance was determined by one-way ANOVA followed by multiple comparison with Duvett
correction. *p < 0.05, **p < 0.01.
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by protection of 11 with the Boc group to give building block 12. We
exemplified this by the preparation of the peptide conjugates 3, 4 and 5
that contain the TLR-7 ligand attached to different positions within the
peptide sequence. Biological evaluation of these conjugates showed that
the prepared conjugates are functional and that the position of the li-
gand influences immunogenicity. We observed induction of dendritic
cell maturation upon conjugation both at the N- and C-terminal posi-
tion, indicating TLR signalling. Specifically, the C-terminal conjugate
displayed a higher activity at lower concentrations. This could be ex-
plained by differential accessibility of the ligand to the TLR7 receptor
depending either on the physical position of the ligand on the peptide
or its interaction with the adjacent amino acids. Secondly, we show that
all conjugates display proper epitope processing and enhanced antigen
presentation, suggesting that conjugation of the ligand allows protea-
some-mediated cleavage. However, the two N-terminal conjugates in-
duced higher T cell proliferation compared to the C-terminal conjugate.
As C-terminal hydrolytic cleavage by the proteasome is crucial for ef-
ficient T cell epitope generation24, the TLR7- ligand at the C-terminal
position of the peptide may interfere with the proteolytic process. As
efficient antigen presentation is fundamental for effective induction of
T cell responses, we argue that N-terminal conjugation may be pre-
ferred for future development of covalent peptide-based vaccines.
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